Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
FcRn Antagonism Leads to a Decrease of Desmoglein-Specific B Cells: Secondary Analysis of a Phase 2 Study of Efgartigimod in Pemphigus Vulgaris and Pemphigus Foliaceus.
Maho-Vaillant M, Sips M, Golinski ML, Vidarsson G, Goebeler M, Stoevesandt J, Bata-Csörgő Z, Balbino B, Verheesen P, Joly P, Hertl M, Calbo S. Maho-Vaillant M, et al. Front Immunol. 2022 May 18;13:863095. doi: 10.3389/fimmu.2022.863095. eCollection 2022. Front Immunol. 2022. PMID: 35663943 Free PMC article. Clinical Trial.
Rituximab and Corticosteroid Effect on Desmoglein-Specific B Cells and Desmoglein-Specific T Follicular Helper Cells in Pemphigus.
Maho-Vaillant M, Perals C, Golinski ML, Hébert V, Caillot F, Mignard C, Riou G, Petit M, Viguier M, Hertl M, Boyer O, Calbo S, Fazilleau N, Joly P. Maho-Vaillant M, et al. J Invest Dermatol. 2021 Sep;141(9):2132-2140.e1. doi: 10.1016/j.jid.2021.01.031. Epub 2021 Mar 22. J Invest Dermatol. 2021. PMID: 33766510 Free article. Clinical Trial.
The Diversity of Serum Anti-DSG3 IgG Subclasses Has a Major Impact on Pemphigus Activity and Is Predictive of Relapses After Treatment With Rituximab.
Golinski ML, Lemieux A, Maho-Vaillant M, Barray M, Drouot L, Schapman D, Petit M, Hertl M, Boyer O, Calbo S, Joly P, Hébert V. Golinski ML, et al. Among authors: maho vaillant m. Front Immunol. 2022 Mar 15;13:849790. doi: 10.3389/fimmu.2022.849790. eCollection 2022. Front Immunol. 2022. PMID: 35371083 Free PMC article.
Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response.
Colliou N, Picard D, Caillot F, Calbo S, Le Corre S, Lim A, Lemercier B, Le Mauff B, Maho-Vaillant M, Jacquot S, Bedane C, Bernard P, Caux F, Prost C, Delaporte E, Doutre MS, Dreno B, Franck N, Ingen-Housz-Oro S, Chosidow O, Pauwels C, Picard C, Roujeau JC, Sigal M, Tancrede-Bohin E, Templier I, Eming R, Hertl M, D'Incan M, Joly P, Musette P. Colliou N, et al. Sci Transl Med. 2013 Mar 6;5(175):175ra30. doi: 10.1126/scitranslmed.3005166. Sci Transl Med. 2013. PMID: 23467561
IgG N-Glycosylation from Patients with Pemphigus Treated with Rituximab.
Font G, Walet-Balieu ML, Petit M, Burel C, Maho-Vaillant M, Hébert V, Chan P, Fréret M, Boyer O, Joly P, Calbo S, Bardor M, Golinski ML. Font G, et al. Among authors: maho vaillant m. Biomedicines. 2022 Jul 22;10(8):1774. doi: 10.3390/biomedicines10081774. Biomedicines. 2022. PMID: 35892674 Free PMC article.
18 results